IL17A and psoriasis: Given its established role in autoimmunity, IL-17A blocking antibodies, such as secukinumab and ixekizumab, have received U.S. Food and Drug Administration (FDA) approval for the treatment of psoriasis, ankylosing spondylitis (AS), and psoriatic arthritis (5).